Tamoxifen in Duchenne Muscular Dystrophy (TAMDMD)

Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial

A randomised, double blind, placebo controlled, 48-week clinical trial with a core population (group A) of 79 ambulant 6.5 to 12 years old Duchenne's muscular dystrophy (DMD) patients that are under stable standard treatment of care with glucocorticoids. Furthermore, the investigators plan to include 6-20 non-ambulant patients who do not receive glucocorticoids (as parallel group B), 10 to 16 years old, to obtain efficacy and safety data in a broader DMD population. All patients will receive 20 mg of tamoxifen (TAM) or placebo once daily during 48 weeks.

An open label extension (OLE) trial for participants of the TAMDMD main study will be performed. All TAMDMD patients on TAM or placebo are offered to enter this OLE.

Study Overview

• Status: Completed
• Conditions: Duchenne Muscular Dystrophy
• Intervention / Treatment: Drug: Tamoxifen; Drug: Matching placebo

Detailed Description

This is a 48-week multicentre, parallel, randomised, double-blind, placebo controlled phase 3 safety and efficacy trial. There are two treatment arms: Tamoxifen (verum) and placebo (control), with treatment allocation of 1:1.

The investigators plan to screen at least 79 and to enroll at least 71 ambulant DMD patients aged between 6.5 and 12 years (group A) and 6 - 20 non-ambulant DMD patients aged between 10 and 16 years (group B). In order to reach statistical power, 60 ambulant patients (group A) need to complete the trial. Treatment with 20 mg Tamoxifen once daily will be given for the total trial duration of 48 weeks.

Only patients with glucocorticoids (standard treatment of care) will be included in group A (ambulant patients) and only non-glucocorticoid users in group B. At baseline as well as at the end of the study clinical, laboratory, and MRI measurements will be performed. These include the Motor Function Measure (MFM) scale, timed function tests, the 6 minute walking distance, quantitative muscle testing (QMT) and quantitative thigh muscle MRI, questionnaires. A physical examination, an ECG, vital signs as well as safety laboratory blood analyses will be performed at every visit. Furthermore, an x-ray of the hand and a dual energy x-ray absorptiometry (DEXA)-scan will be performed at baseline and at the end of the study.

An open label extension (OLE) trial for participants of the TAMDMD main study will be performed. All TAMDMD patients on TAM or placebo are offered to enter this OLE. All OLE patients will receive 20 mg of TAM daily during 48 weeks. The same study specific assessments as in the double-blind randomized phase will be performed during the OLE phase

• Study Type: Interventional
• Enrollment (Actual): 93
• Phase: Phase 3

Contacts and Locations

Study Locations

• France
  • Garches, France, 92380
    • Hôpitaux Raymond Poincaré
  • Strasbourg, France, 67098
    • Hôpital de Hautepierre
• Germany
  • Berlin, Germany, 14050
    • DRK Klinik Berlin Westend
  • Essen, Germany, 45147
    • Universitätsklinikum Essen
• Netherlands
  • Nijmegen, Netherlands, 6525
    • Radboud UMC
• Spain
  • Sevilla, Spain, 41013
    • Hospital Universitario Virgen del Rocio
  • Barcelona
    • Esplugues de Llobregat, Barcelona, Spain, 08950
      • Hospital Sant Joan de Déu. UB
• Switzerland
  • Basel, Switzerland, 4031
    • University Children's Hospital Basel
• United Kingdom
  • Glasgow, United Kingdom, G51 4TF
    • Royal Hospital for Children
  • Leeds, United Kingdom, LS9 7TF
    • The Leeds Teaching Hospitals Nhs Trust
  • Liverpool, United Kingdom, L12 2AP
    • Alder Hey Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 16 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

Group A (ambulant patients)

• Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent or <5% of normal) on Western blot or immunostaining
• Stable treatment with glucocorticoids >6 months (no significant change in dosage (>0.2mg/kg)) at screening; dosing adaptations according to weight change are allowed
• Male gender
• 6.5 to 12 years of age at time of screening
• weight >20kg
• ambulant patients
• able to walk at least 350 meters in 6 minute walking distance test without assistance at screening
• MFM D1 subdomain of the MFM scale >40% at screening
• Ability to provide informed consent and to comply with study requirements
• Patients harbouring a nonsense mutation treatable with the approved drug ataluren should be under stable ataluren treatment for at least 3 months or in case of nontolerance being off ataluren treatment for at least 3 months before screening

Group B (non-ambulant patients)

• Documented diagnosis of DMD by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent or <5% of normal) on Western blot or immunostaining
• Not using glucocorticoids for >6 months
• Male gender
• Non-ambulant patients (walking distance less than 10 meters)
• 10 to 16 years of age at time of screening
• Ability to provide informed consent and to comply with study requirements

Open label extension

- Recent participation and completion of TAMDMD study

Exclusion Criteria:

• Known individual hypersensitivity or allergy to tamoxifen or other ingredients/excipients of IMP
• Female gender
• Use of tamoxifen or testosterone within the last 3 months
• Known or suspected malignancy
• Other chronic disease or clinically relevant limitation of renal, liver or heart function
• Known or suspected non-compliance
• Any injury which may impact functional testing, e.g. upper or lower limb fracture
• Planned or expected spinal fusion surgery during the study period (as judged by the Investigator; i.e. due to rapid progressing scoliosis), previous spinal fusion surgery is allowed if it took place more than 6 months prior to screening.
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders of the participant/parents (as judged by the investigator)
• Concomitant participation in any other interventional trial (and up to 3 months prior to screening)
• Use of CYP2D6 inhibitors or of CYP3A4 inducers (apart from glucocorticoids), platelet aggregation inhibitors and coumarin-type anti-coagulants
• Use of drugs metabolized by CYP2C9, such as phenprocoumon, phenytoin, warfarin, celecoxib, fluvastatin, ginko biloba, St. John's wort and sulfamethoxazol
• Galactosemia (lack of galactose-1-phosphat-uridylyltransferase or UDP-galactose-4-epimerase or galactokinase; Fanconi-Bickel-syndrome); congenital lack of lactase; glucose-galactose malabsorption
• Presence of one or more of the following eye disorders: cataract, retinopathia, optic neuropathy, alteration of the cornea
• Presence of one or more of the following laboratory abnormalities: anaemia, thrombocytopenia, leukopenia, neutropenia or agranulocytosis

Group A:

• Glucocorticoid naïve patients
• Start of glucocorticoid treatment or change in dosage <6 month prior to screening (dosing adaptations according to weight change are allowed)

Group B:

• Glucocorticoid treated patients or patients that stopped glucocorticoid treatment <6 month prior to screening
• Assisted ventilation of any kind necessary

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tamoxifen 20 mg once daily; DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.	Drug: Tamoxifen; DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
Placebo Comparator: Matching placebo once daily; Patients randomised to placebo will be administered matching placebo.	Drug: Matching placebo; Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction of disease progression	To test if tamoxifen treatment, compared to placebo, reduces the progression of the disease in 6.5-12 years old ambulant DMD patients (Group A) by at least 50% (using the MFM D1 subscore as primary clinical endpoint).	Baseline to week 48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle function measured by D2 MFM subscore	D2 MFM subscore from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle function measured by D3 MFM subscore	D3 MFM subscore from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle function measured by North Star Ambulatory Assessment	North Star Ambulatory Assessment from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle function measured by proximal upper limb function	Proximal upper limb function from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle function measured by 6 minute walking distance in meter	6 minute walking distance in meter from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle function measured by 10 meter walking time in seconds	10 meter walking time in seconds from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle function measured by time to rise from lying on the floor / supine up in seconds	time to rise from lying on the floor / supine up in seconds from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle force measured by quantitative muscle testing (using Myogrip)	Quantitative muscle testing (using Myogrip) from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48
Muscle Degeneration measured by MRI	Quantitative muscle MRI including muscle fat fraction (MFF) and T2 times of thigh muscles visualised by MRI from baseline to week 48 under TAM treatment compared to placebo.	Baseline to week 48

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient reported outcome measured by PARS III questionnaire	Personal Adjustment and Role Skills Scale (PARS-III) from baseline to week 48 under TAM treatment under TAM treatment compared to placebo.	Baseline to week 48

Collaborators and Investigators

• Sponsor: University Hospital, Basel, Switzerland
• Investigators: Principal Investigator: Dirk Fischer, MD, University Children's Hospital Basel

Publications and helpful links

General Publications

• Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schadelin S, Bieri O, Fischer D. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials. 2019 Nov 21;20(1):637. doi: 10.1186/s13063-019-3740-6.

Study record dates

Study Major Dates

• Study Start (Actual): June 12, 2018
• Primary Completion (Actual): July 25, 2022
• Study Completion (Actual): October 18, 2022

Study Registration Dates

• First Submitted: October 10, 2017
• First Submitted That Met QC Criteria: November 21, 2017
• First Posted (Actual): November 27, 2017

Study Record Updates

• Last Update Posted (Actual): December 20, 2022
• Last Update Submitted That Met QC Criteria: December 19, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Keywords: DMD
• Additional Relevant MeSH Terms: Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Musculoskeletal Diseases; Muscular Diseases; Neuromuscular Diseases; Muscular Disorders, Atrophic; Muscular Dystrophies; Muscular Dystrophy, Duchenne; Physiological Effects of Drugs; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Hormone Antagonists; Bone Density Conservation Agents; Estrogen Antagonists; Selective Estrogen Receptor Modulators; Estrogen Receptor Modulators; Tamoxifen
• Other Study ID Numbers: TAMDMD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No